Want to see HYPD full AI Analyst Report?
HYPD Stock Chart & Stats
$2.51
-$0.13(-4.92%)
At close: 4:00 PM EDT
$2.51
-$0.13(-4.92%)
Day’s Range― - ―
52-Week Range$2.34 - $15.00
Previous CloseN/A
Volume268.32K
Average Volume (3M)1.09M
Market Cap
$40.02M
Enterprise Value$52.87
Total Cash (Recent Filing)$7.38M
Total Debt (Recent Filing)$9.07M
Price to Earnings (P/E)―
Beta3.07
Next Earnings
Nov 18, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.46
Shares Outstanding15,157,747
10 Day Avg. Volume701,310
30 Day Avg. Volume1,085,571
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.43
Price to Sales (P/S)21.88
P/FCF Ratio-1.21
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.20Price Target Upside186.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.78
Revenue Forecast (FY)$7.02M
Bulls Say, Bears Say
Bulls Say
Collaboration OpportunitiesCollaborations in dry eye disease development are seen as upside, with the user-filled Optejet potentially defining the most realistic shot for near-term progress.
Merger And DevelopmentThe proposed merger of topical ophthalmic platforms could present the next constructive chapter for Optejet and broader development.
Technological AdvancementThe new user-filled Optejet incorporates a sterile disposable cartridge that can be user-filled from a traditional eyedropper bottle, allowing consistent and precise spray delivery.
Bears Say
Clinical Trial ChallengesThe Phase 3 CHAPERONE trial failure for MicroPine has informed the assumptions for the price target.
Discontinued TrialsThe Phase 3 CHAPERONE trial using the Optejet optimized spray dispenser for delivering MicroPine atropine for reduction of pediatric progressive myopia was discontinued.
Market And Revenue RisksRisks to the investment thesis include failure of products and/or candidates to achieve peak commercial revenue estimates due to market size, penetration rates, and/or pricing.
Hyperion DeFi News
HYPD FAQ
What was Hyperion DeFi’s price range in the past 12 months?
Hyperion DeFi lowest stock price was $2.34 and its highest was $15.00 in the past 12 months.
What is Hyperion DeFi’s market cap?
Hyperion DeFi’s market cap is $40.02M.
When is Hyperion DeFi’s upcoming earnings report date?
Hyperion DeFi’s upcoming earnings report date is Nov 18, 2026 which is in 96 days.
How were Hyperion DeFi’s earnings last quarter?
Hyperion DeFi released its earnings results on Aug 12, 2026. The company reported $1.01 earnings per share for the quarter, missing the consensus estimate of $2.24 by -$1.23.
Is Hyperion DeFi overvalued?
According to Wall Street analysts Hyperion DeFi’s price is currently Undervalued.
Does Hyperion DeFi pay dividends?
Hyperion DeFi does not currently pay dividends.
What is Hyperion DeFi’s EPS estimate?
Hyperion DeFi’s EPS estimate is -0.33.
How many shares outstanding does Hyperion DeFi have?
Hyperion DeFi has 15,157,747 shares outstanding.
What happened to Hyperion DeFi’s price movement after its last earnings report?
Hyperion DeFi reported an EPS of $1.01 in its last earnings report, missing expectations of $2.24. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Hyperion DeFi?
Currently, no hedge funds are holding shares in HYPD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hyperion DeFi Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.20 (186.85% Upside)
$7.20 (186.85% Upside)
Insider Transactions
Bought Shares
Worth $29.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-82.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1070.90%
Trailing 12-Months
Company Description
Hyperion DeFi
Operating from the United States, Hyperion DeFi, Inc. is a company undergoing a significant shift from its foundational work in ophthalmic drug-delivery, known as Optejet. Its current trajectory involves establishing itself as the inaugural U.S. firm on Nasdaq to hold a cryptocurrency treasury, predominantly denominated in HYPE tokens originating from the Hyperliquid blockchain. Furthermore, Hyperion DeFi oversees the "Kinetiq × Hyperion" validator, persists with its decentralized finance (DeFi) staking strategies, and continues to advance its Optejet UFD™ technology for ocular health.
HYPD Company Deck
HYPD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented substantial positive developments: strong treasury accumulation (56% growth), large unrealized treasury gains, record quarterly net income and adjusted EBITDA, meaningful quarter-over-quarter growth in adjusted gross profit and multiple operational wins (product launches, partnerships, rapid redeployment of HYPE). However, the USDH-to-USDC transition created a material short-term headwind (800,000 HYPE redeployments) that depressed DeFi monetization (-36% q/q) and highlighted volatility in ecosystem rewards and GAAP cash reporting. Management demonstrated quick strategic responses (1.0M HYPE redeployed into new partnerships, new HAUS deals, first institutional credit deal), continued expense reductions (core op expenses down ~46% vs. Q3'25), and pipeline traction, which together outweigh the temporary setbacks. Overall, positives notably outweigh the lowlights, though the business remains exposed to token-price sensitivity and ecosystem timing risks.View all HYPD earnings summariesHYPD Stock 12 Month Forecast
Average Price Target
$7.20
▲(186.85% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Baird Medical Investment Holdings
―
Ownership Overview
15.51% Insiders
2.48% Mutual Funds
3.50% Other Institutional Investors
75.21% Public Companies and
Individual Investors